OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
-2.06%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$568M
AUM Growth
+$568M
(-21%)
Cap. Flow
-$6.3M
Cap. Flow
% of AUM
-1.11%
Top 10 Holdings %
Top 10 Hldgs %
73.26%
Holding
45
New
3
Increased
12
Reduced
12
Closed
8
Top Buys
| 1 |
Insmed
INSM
|
$23.2M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$19.5M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
$12.7M |
| 4 |
Taysha Gene Therapies
TSHA
|
$8.78M |
| 5 |
Roivant Sciences
ROIV
|
$5.41M |
Top Sells
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
$22.3M |
| 2 |
Disc Medicine
IRON
|
$18.4M |
| 3 |
Tandem Diabetes Care
TNDM
|
$11.7M |
| 4 |
Travere Therapeutics
TVTX
|
$7.6M |
| 5 |
Geron
GERN
|
$7.31M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $119M | 18.29% | 3,130,000 +511,700 | +20% | +$19.5M |
|
|
2
Roivant Sciences
ROIV
$8.15B
| $51M | 7.84% | 4,367,000 +463,000 | +12% | +$5.41M |
|
|
CBAY
3
DELISTED
Cymabay Therapeutics
CBAY
| $45.8M | 7.04% | 3,073,750 -1,497,168 | -33% | -$22.3M |
|
|
VRNA
4
Verona Pharma
VRNA
$9.16B
| $38.6M | 5.93% | 2,369,000 -99,000 | -4% | -$1.61M |
|
5
Arcus Biosciences
RCUS
$1.13B
| $35.3M | 5.43% | 1,968,000 | – | – |
|
|
6
Insmed
INSM
$28.8B
| $32.4M | 4.98% | 1,284,000 +917,000 | +250% | +$23.2M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $28.5M | 4.38% | 655,051 -94,949 | -13% | -$4.14M |
|
8
BridgeBio Pharma
BBIO
$9.89B
| $25.6M | 3.94% | 971,639 -247,561 | -20% | -$6.53M |
|
9
Celldex Therapeutics
CLDX
$1.47B
| $20.9M | 3.21% | 759,898 | – | – |
|
10
89bio
ETNB
$1.34B
| $18.8M | 2.89% | 1,219,157 +152,373 | +14% | +$2.35M |
|
|
OKUR
11
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $17.4M | 2.67% | 2,279,870 -88,717 | -4% | -$676K |
|
12
Viridian Therapeutics
VRDN
$1.5B
| $16.4M | 2.52% | 1,067,143 +144,143 | +16% | +$2.21M |
|
13
AN2 Therapeutics
ANTX
$30.1M
| $14M | 2.14% | 867,575 +146,675 | +20% | +$2.36M |
|
|
14
Amylyx Pharmaceuticals
AMLX
$836M
| $12.7M | 1.96% | +695,000 | New | +$12.7M |
|
|
15
Taysha Gene Therapies
TSHA
$797M
| $8.78M | 1.35% | +2,777,778 | New | +$8.78M |
|
|
ALPN
16
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $8.59M | 1.32% | 750,000 | – | – |
|
17
Gossamer Bio
GOSS
$562M
| $6.82M | 1.05% | 8,187,883 +4,229,814 | +107% | +$3.52M |
|
|
JBIO
18
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $6.75M | 1.04% | 497,370 -124,342 | -20% | -$1.69M |
|
19
Dianthus Therapeutics
DNTH
$759M
| $6.56M | 1.01% | 480,000 -70,000 | -13% | -$957K |
|
20
Dyne Therapeutics
DYN
$1.92B
| $6.21M | 0.95% | 692,945 | – | – |
|
21
PMV Pharmaceuticals
PMVP
$74.2M
| $5.55M | 0.85% | 904,000 +434,000 | +92% | +$2.66M |
|
|
INZY
22
DELISTED
Inozyme Pharma
INZY
| $5.46M | 0.84% | 1,300,000 +1,250,298 | +2,516% | +$5.25M |
|
23
Xilio Therapeutics
XLO
$36.3M
| $4.89M | 0.75% | 2,318,500 -106,500 | -4% | -$225K |
|
24
Annexon
ANNX
$226M
| $4.84M | 0.74% | 2,050,000 +390,000 | +23% | +$920K |
|
|
CBIO
25
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $4.5M | 0.69% | 3,000,000 | – | – |
|